Cesta CE, Rotem R, Bateman BT, et al
In fact, high-profile examples of payers pulling back on coverage are stacking up: North Carolinas state health plan dropped GLP-1s after spending $100 million, Ascension eliminated all weight-loss drug coverage, and Mayo Clinic capped lifetime GLP-1 benefits at $20,000
Stopping the medication to address temporary hair loss could compromise these important health benefits
On February 20, 2026 the FDA issued Warning Letter #717989 to Lean Rx, Inc
[1] Retatrutide: What the Evidence Actually Shows Retatrutides pivotal obesity dataset is a Phase 2, double-blind, randomised, placebo-controlled trial in adults with obesity (or overweight plus a weight-related condition), testing once-weekly doses up to 12 mg over 48 weeks